Setting the Record Straight: Utility and Outcomes in Patients With HCV Related HCC
Journal of Viral Hepatitis · 2026
DOI: 10.1111/jvh.70148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2026. Verfasst von María Fernanda Guerra-Veloz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Liver Studies, King's College Hospital, London, UK. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Antiviral Agents, Liver Neoplasms, Hepatitis C, Chronic. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
The effectiveness of direct acting antiviral (DAA) therapy in patients with active hepatocellular carcinoma (HCC) is poorly defined. NHS England approved DAA therapy for all viraemic patients, including those with HCC. The aim of this retrospective study is to provide a real‐life data of treatment outcomes in those with active HCC. Patients with HCV related HCC from the National Hepatitis C registry in South‐East England between 2016 and 2023 were included. The primary outcome was to assess the HCV care cascade in patients with HCV related HCC (HCC cohort) in comparison with those with advanced fibrosis/cirrhosis without HCC (non‐HCC cohort). 1518 HCV RNA‐positive patients started DAA therapy. 92.4% (1403) were included in the non‐HCC cohort and 7.6% (115) were included in the HCC cohort. The SVR rate in the HCC cohort was 87% (80/92) versus 94.5% (1126/1191) in the non‐HCC cohort ( p = 0.003). In the multivariate analysis, only the presence of HCC (OR 0.4 95% CI 0.2–0.9; p = 0.029) was associated with a lower probability of achieving SVR. SVR rates were 95.6%, 50%, 75% and 22.2% and the median overall survival (OS) was 80, 29, 17 and 3 months for BCLC 0‐A/B/C/D respectively. OS was longer in those who achieved SVR. More than two thirds of patients with HCV‐related HCC initiated and completed DAA therapies. This high level of treatment uptake has led to an acceptable cure rate. Treating patients with HCV and HCC should be viewed as an appropriate clinical standard to improve overall outcomes. However, DAA therapy should not be initiated in those with a short life expectancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Liver Studies, King's College Hospital, London, UK.
- NHS England & NHS Improvement, HCV Elimination, London, UK.
- Department of Oncology, King's College Hospital NHS Foundation Trust, London, UK.
ORCID-Profile: María Fernanda Guerra-Veloz, Kosh Agarwal
Zitieren
APA
Guerra-Veloz, M. F., Shah, S., Emmanouil, B., Olsen, M., George, R., Selemani, S., Ross, P. J., Carey, I., Mehta, N., Gillyon-Powell, M., & Agarwal, K. (2026). Setting the Record Straight: Utility and Outcomes in Patients With HCV Related HCC. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.70148
Vancouver
Guerra-Veloz MF, Shah S, Emmanouil B, Olsen M, George R, Selemani S, et al. Setting the Record Straight: Utility and Outcomes in Patients With HCV Related HCC. Journal of Viral Hepatitis. 2026. doi:10.1111/jvh.70148
BibTeX
@article{GuerraVeloz2026,
author = {Guerra-Veloz, María Fernanda and Shah, Sital and Emmanouil, Beatrice and Olsen, Mia and George, Renita and Selemani, Sarah and Ross, Paul J and Carey, Ivana and Mehta, Neha and Gillyon-Powell, Mark and Agarwal, Kosh},
title = {Setting the Record Straight: Utility and Outcomes in Patients With HCV Related HCC},
journal = {Journal of Viral Hepatitis},
year = {2026},
doi = {10.1111/jvh.70148}
}
EUVIMED